Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Several Ohio medical spas including two in the Mahoning Valley were sent letters by the Ohio Attorney General's Office ...

By December 2023, 12.3% of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM.

The Ohio attorney general's office issues warning letters to more than a dozen medical spas across the state for misleading claims about compounded versions of Ozempic, Wegovy and Mounjaro.

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...